

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 April 2022 (14.04.2022)



(10) International Publication Number
WO 2022/076975 A1

(51) International Patent Classification:

C07D 239/94 (2006.01) A61K 31/517 (2006.01)
C07D 495/04 (2006.01)

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(21) International Application Number:

PCT/US2021/071695

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(22) International Filing Date:

04 October 2021 (04.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/087,763 05 October 2020 (05.10.2020) US
63/224,236 21 July 2021 (21.07.2021) US

(71) Applicant: **ENLIVEN THERAPEUTICS, INC.**
[US/US]; 6200 Lookout Road, Floor 1, Boulder, Colorado
80301-3319 (US).

(72) Inventors: **LYSSIKATOS, Joseph P.**; c/o EnLiven Therapeutics, Inc., 6200 Lookout Road, Floor 1, Boulder, Colorado 80301-3319 (US). **KINTZ, Samuel**; c/o EnLiven Therapeutics, Inc., 6200 Lookout Road, Floor 1, Boulder, Colorado 80301-3319 (US). **REN, Li**; c/o EnLiven Therapeutics, Inc., 6200 Lookout Road, Floor 1, Boulder, Colorado 80301-3319 (US).

(74) Agent: **CHOING, Stephanie** et al.; Morrison & Foerster LLP, 425 Market Street, San Francisco, California 94105 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES

(57) Abstract: The present disclosure relates to compounds and compositions for inhibition of Bcr- Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).

WO 2022/076975 A1